Abstract 38P
Background
Regulatory T cells (Treg) play a crucial role as prognostic factors and intervention targets for isocitrate dehydrogenase (IDH)-wild type (wt) glioblastoma (GBM). The study aimed to construct a model predicting the Treg infiltration in IDH-wt GBM patients using pathomics techniques and explore related biological processes.
Methods
Flow cytometry was used to detect the proportion of Treg in orthotopic mouse glioblastoma brain tissue. Clinical data of IDH-wt GBM patients from the TCGA database were analyzed retrospectively. Features were extracted from HE-stained biopsy sections using the Pyradiomics package. The pathomics model was constructed using the Gradient Boosting Machine algorithm after performing feature selection with mRMR and Relief algorithms. Cox proportional hazard regression analysis was employed to access the association between pathomics score (PS) and overall survival (OS). Transcriptomic data were analyzed through GSEA set enrichment, differential gene expression, and correlation analyses.
Results
The study established a pathomics model with 3 pathomics features that effectively predicted Treg infiltration (Training set: AUC=0.807; Validation set: AUC=0.735). PS positively correlated with high Treg expression. Survival analysis indicated that patients with high PS had significantly lower OS than the low PS group (median survival time: 12.0 vs 14.4 months; p=0.009). Multivariate COX analysis revealed that high PS expression independently served as a prognostic risk factor for IDH-wt GBM patients (HR, 2.16; 95% CI, 1.269-3.677; p=0.005). Subgroup analysis showed that high PS was a risk factor for OS in patients receiving chemotherapy (HR, 2.232; 95% CI, 1.309-3.905; p=0.003) or radiotherapy (HR, 1.882; 95% CI, 1.161-3.049; p=0.01).GSEA enrichment analysis revealed significant associations of PS with the NOTCH, IL-6/JAK/STAT3 signaling pathways. High PS significantly correlated with elevated RAD50 expression.
Conclusions
The developed pathomics model, based on machine learning algorithms, can noninvasively predict Treg infiltration and prognosis in IDH-wt GBM patients. The biological processes related to the model may involve RAD50 and pathways, including NOTCH, IL-6/JAK/STAT3.
Legal entity responsible for the study
The authors.
Funding
The Joint Funds for the Innovation of Science and Technology, Fujian Province (No.2021Y9301).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - Progression-Free Survival is an acceptable surrogate endpoint for chemo-immunotherapy combinations in Cervical Carcinoma, an EORTC Young GCG study
Presenter: Ramon Yarza
Session: Poster Display
102P - Interim safety analysis of a phase 2 trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer
Presenter: Oladapo Yeku
Session: Poster Display
103P - Long-term survivorship rates among previously treated patients with advanced renal cell carcinoma (aRCC) achieving objective response with nivolumab
Presenter: Saby George
Session: Poster Display
105P - Preliminary efficacy and safety results from ‘ReBirth’, a phase II study of risk-based bladder-sparing therapy for MIBC.
Presenter: Yijun Shen
Session: Poster Display
106P - Treatment Sequencing in PD-L1-Positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Exploratory Analysis of the Phase 3 KEYNOTE-048 Study
Presenter: Amanda Psyrri
Session: Poster Display
108P - Real-world (RW) effectiveness and safety of adjuvant nivolumab (NIVO) in patients (pts) with melanoma in Belgium and Luxembourg: PRESERV MEL
Presenter: Bart Neyns
Session: Poster Display
109P - Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy
Presenter: Inge Noringriis
Session: Poster Display
110P - Outcomes of CUPem: A prospective Phase II multicentre clinical Trial of Pembrolizumab in patients with pre-treated Cancer of Unknown Primary
Presenter: Harpreet Wasan
Session: Poster Display
111P - Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
Presenter: Ciro Celsa
Session: Poster Display